Search details
1.
Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2.
Nephrol Dial Transplant
; 34(6): 1000-1008, 2019 06 01.
Article
in English
| MEDLINE | ID: mdl-30053159
2.
The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma.
Pediatr Nephrol
; 33(1): 101-109, 2018 Jan.
Article
in English
| MEDLINE | ID: mdl-28993887
3.
Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study.
Lancet
; 388(10056): 2153-2163, 2016 10 29.
Article
in English
| MEDLINE | ID: mdl-27613521
4.
Safety of Everolimus in Patients Younger than 3 Years of Age: Results from EXIST-1, a Randomized, Controlled Clinical Trial.
J Pediatr
; 172: 151-155.e1, 2016 05.
Article
in English
| MEDLINE | ID: mdl-26858193
5.
Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.
Ann Neurol
; 78(6): 929-38, 2015 Dec.
Article
in English
| MEDLINE | ID: mdl-26381530
6.
Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.
Nephrol Dial Transplant
; 31(1): 111-9, 2016 Jan.
Article
in English
| MEDLINE | ID: mdl-26156073
7.
Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.
Lancet Oncol
; 15(13): 1513-1520, 2014 Dec.
Article
in English
| MEDLINE | ID: mdl-25456370
8.
The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.
Nephrol Dial Transplant
; 29(6): 1203-10, 2014 Jun.
Article
in English
| MEDLINE | ID: mdl-24729041
9.
Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors.
Pediatr Blood Cancer
; 61(10): 1792-7, 2014 Oct.
Article
in English
| MEDLINE | ID: mdl-24962521
10.
Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials.
Haematologica
; 103(1): e25-e28, 2018 01.
Article
in English
| MEDLINE | ID: mdl-29051280
11.
Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase.
Br J Clin Pharmacol
; 68(6): 920-7, 2009 Dec.
Article
in English
| MEDLINE | ID: mdl-20002087
12.
Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia.
Leuk Res
; 85: 106197, 2019 10.
Article
in English
| MEDLINE | ID: mdl-31541945
13.
Pooled analysis of menstrual irregularities from three major clinical studies evaluating everolimus for the treatment of tuberous sclerosis complex.
PLoS One
; 12(10): e0186235, 2017.
Article
in English
| MEDLINE | ID: mdl-29023494
14.
Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study.
PLoS One
; 12(8): e0180939, 2017.
Article
in English
| MEDLINE | ID: mdl-28792952
15.
Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study.
PLoS One
; 11(6): e0158476, 2016.
Article
in English
| MEDLINE | ID: mdl-27351628
Results
1 -
15
de 15
1
Next >
>>